CV DEATH HAS A NEW OPPONENT
CV DEATH HAS A NEW OPPONENT

Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF

Document ID: PC-PH-103702

06/12/2022

Author: Boehringer Ingelheim

Related content

 
PC-PH-103702
Production date: December 2022